Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003263 · ClinicalTrials.gov registry record · Phase 1
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
A Phase 1 study of Malignant Mesothelioma, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT00003263 is a Phase 1 study of Malignant Mesothelioma that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 6 participants, below the 76-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00003263, a Phase 1 study of Malignant Mesothelioma, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy, radiation therapy, and interferon alfa may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of cisplatin plus interferon alfa followed by surgery and interferon alfa plus radiation therapy in treating patients with malignant pleural mesothelioma.
Conditions Studied
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- BIOLOGICAL recombinant interferon alfa
- PROCEDURE surgical procedure
Study Locations (3)
Louisiana
- Office of S. Terry Kraus - Marrero
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Virginia
- Virginia Oncology Associates - Newport News
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1996-08 |
| Est. Completion | 2000-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003263
The ClinicalTrials.gov registry entry for NCT00003263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (92% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00003263 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Louisiana, Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT00003263 about?
NCT00003263 is a clinical study titled "Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy, radiation therapy, and inter...
What is the current status of trial NCT00003263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 1996-08. Estimated completion is 2000-11.
What conditions does trial NCT00003263 study?
This clinical trial studies the following conditions: Malignant Mesothelioma.
What interventions are being tested in trial NCT00003263?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), recombinant interferon alfa (BIOLOGICAL), surgical procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00003263?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003263 being conducted?
This trial has 3 study locations across Louisiana, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
-
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
RECRUITING · Phase 1
-
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
COMPLETED · Phase 1
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.